Cantor Fitzgerald Predicts Ardelyx FY2025 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Ardelyx in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical company will post earnings of ($0.13) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. The business had revenue of $116.13 million during the quarter, compared to the consensus estimate of $111.16 million. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%.

ARDX has been the topic of a number of other reports. Raymond James restated a “strong-buy” rating and set a $13.00 price target (down from $15.00) on shares of Ardelyx in a report on Friday, February 21st. BTIG Research began coverage on shares of Ardelyx in a report on Tuesday. They issued a “buy” rating and a $14.00 price target for the company. Piper Sandler upped their price objective on shares of Ardelyx from $7.00 to $8.00 and gave the company a “neutral” rating in a report on Monday, January 27th. HC Wainwright reaffirmed a “neutral” rating and issued a $5.50 target price on shares of Ardelyx in a research report on Friday, February 21st. Finally, Jefferies Financial Group dropped their price target on Ardelyx from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, January 2nd. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.44.

Ardelyx Trading Down 2.2 %

NASDAQ:ARDX opened at $5.32 on Thursday. Ardelyx has a 52 week low of $4.32 and a 52 week high of $9.61. The firm’s fifty day moving average is $5.38 and its 200-day moving average is $5.60. The firm has a market cap of $1.27 billion, a P/E ratio of -33.25 and a beta of 0.85. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.31 and a current ratio of 4.58.

Insider Buying and Selling

In related news, Director David M. Mott purchased 77,729 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were bought at an average cost of $5.00 per share, with a total value of $388,645.00. Following the acquisition, the director now owns 2,015,494 shares of the company’s stock, valued at $10,077,470. This represents a 4.01 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael Raab sold 41,666 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $5.31, for a total transaction of $221,246.46. Following the sale, the chief executive officer now owns 1,129,552 shares of the company’s stock, valued at $5,997,921.12. This trade represents a 3.56 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 490,029 shares of company stock worth $2,377,766 and have sold 141,408 shares worth $761,963. 5.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ardelyx

Several institutional investors have recently bought and sold shares of ARDX. State Street Corp raised its stake in shares of Ardelyx by 1.5% in the third quarter. State Street Corp now owns 12,141,850 shares of the biopharmaceutical company’s stock valued at $83,657,000 after buying an additional 176,789 shares during the period. Rubric Capital Management LP lifted its holdings in Ardelyx by 68.5% during the third quarter. Rubric Capital Management LP now owns 3,060,191 shares of the biopharmaceutical company’s stock valued at $21,085,000 after purchasing an additional 1,243,606 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Ardelyx by 274.3% during the third quarter. BNP Paribas Financial Markets now owns 181,387 shares of the biopharmaceutical company’s stock worth $1,250,000 after purchasing an additional 132,928 shares during the period. Vestal Point Capital LP purchased a new position in shares of Ardelyx in the third quarter worth about $3,445,000. Finally, JPMorgan Chase & Co. raised its position in shares of Ardelyx by 1.6% in the third quarter. JPMorgan Chase & Co. now owns 387,144 shares of the biopharmaceutical company’s stock valued at $2,667,000 after purchasing an additional 6,093 shares during the period. Hedge funds and other institutional investors own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.